United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.

Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic companies, which ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), JPMorgan Chase ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), United Therapeutics (UTHR – Research Report) and Universal ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best healthcare stocks for long-term investment. In the US, healthcare ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best healthcare stocks for long-term investment. In the US, healthcare ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA. Read a portfolio update here.